Searchable abstracts of presentations at key conferences in endocrinology

ea0081p285 | Adrenal and Cardiovascular Endocrinology | ECE2022

Prognostic value of endocrine biomarkers in patients admitted to intensive care unit for COVID-19

Varaldo Emanuele , Maria Berton Alessandro , Rosata Andrea , Montrucchio Giorgia , Rumbolo Francesca , Prencipe Nunzia , Ghigo Ezio , Brazzi Luca , Grottoli Silvia

Introduction: To date, there are no clear biochemical parameters to identify early COVID-19 cases at risk of complications in the Intensive Care Unit (ICU). Aim: To evaluate the prognostic potential of endocrine biomarkers associated with acute inflammatory conditions in ICU patients for COVID-19.Methods: Between 1/3/2020 and 31/12/2020 we recruited 126 consecutive patients at the admission to ICU 1U, Molinette University Hospital ...

ea0081p663 | Pituitary and Neuroendocrinology | ECE2022

GH-secreting pituitary adenoma: dura mater invasion is not a predictor of acromegaly persistence after trans-sphenoidal surgery

Prencipe Nunzia , Diperna Giuseppe , MARIA BERTON ALESSANDRO , Baldassarre Bianca , Bona Chiara , De Marco Raffaele , Bioletto Fabio , Grottoli Silvia , Zenga Francesco

Background: Despite the benign nature of pituitary adenomas, microscopic examination of surgical specimens showed that dural invasion occurs in about 42-85% of cases. No studies about dura mater invasion were conducted specifically in acromegaly, so the aim of the present study was to evaluate the relationship between histologically verified dural invasion and the “aggressiveness” features of GH-secreting adenomas.Methods: A prospective study i...

ea0037gp.19.06 | Pituitary–Acromegaly | ECE2015

Criteria for disease control in acromegaly under SSA treatment: mean GH profile or GH random?

Prencipe Nunzia , Bona Chiara , Karamouzis Joannis , Berton Alessandro Maria , Di Giacomo Stellina Valentina , Guaraldi Federica , Ghigo Ezio , Grottoli Silvia

Acromegaly is due to increased GH secretion usually sustained by a GH-secreting pituitary adenoma. Somatostatin analogues (SSA) can control GH hypersecretion in 60% of patients and tumor volume in 30%. The disease control is, in turn, associated with lower mortality and therefore to verify the optimal control of the disease activity is of critical importance to adapt the dose and the choice of alternative treatment. The criteria for optimized disease control had been assumed a...

ea0070aep609 | Pituitary and Neuroendocrinology | ECE2020

Biliary stone disease in acromegaly under somatostatinanalogues: A longterm safety study

Prencipe Nunzia , Cuboni Daniela , Bona Chiara , Maria Berton Alessandro , Parasiliti Caprino Mirko , Fenoglio Luigi , Gasco Valentina , Ghigo Ezio , Grottoli Silvia

Introduction: Somatostatin analogues (SSA) are one of the main effective drug used in acromegaly. Sludge and/or cholelithiasis development represents oneof the more common side effect. The aim of the study was to analyze the frequency of biliary adverse events (BAE) and possible predictive factors, to propose a work-up strategy for their management.Method: This is a single centre, longitudinalretrospective study; we enrolled 91 acromegaly patients during...

ea0081rc7.2 | Rapid Communications 7: Pituitary and Neuroendocrinology 2 | ECE2022

Development and internal validation of a predictive score for the diagnosis of central adrenal insufficiency when morning cortisol is in the grey zone

Bioletto Fabio , Maria Berton Alessandro , Varaldo Emanuele , Cuboni Daniela , Bona Chiara , Parasiliti Caprino Mirko , Prencipe Nunzia , Ghigo Ezio , Grottoli Silvia , Maccario Mauro , Gasco Valentina

Background: When evaluating a patient for central adrenal insufficiency (CAI), there is a wide range of morning cortisol values for which no final conclusion on hypothalamus-pituitary-adrenal (HPA) axis function can be drawn; in these cases, a stimulation test is required. Aim of this study was to develop an integrated model for the prediction of CAI when morning cortisol is in the grey zone, here defined as 40.0-160.0 μg/l.Methods: Overall, 119 pat...

ea0081p143 | Pituitary and Neuroendocrinology | ECE2022

Efficacy and safety of long-term high doses of cabergoline in prolactin secreting tumor

Bona Chiara , Prencipe Nunzia , Mazza Enrico , Maria Berton Alessandro , Bioletto Fabio , Varaldo Emanuele , Cuboni Daniela , Gottero Cristina , Gasco Valentina , Ghigo Ezio , Grottoli Silvia

Purpose: The aim of this study was to identify any predictive factors for need of high doses of cabergoline (CAB) in prolactinomas and to study any relationship between adverse events onset and CAB cumulative dose.Methods: Forty-two patients harboring resistant prolactinomas (High Dose group-HD; cabergoline dose ≥ 3.5 mg/week) were matched by gender, age and pituitary tumor diameter at diagnosis with subjects under standard doses (Standard Dose gro...

ea0081p396 | Pituitary and Neuroendocrinology | ECE2022

Precision medicine: new perspectives for the treatment of GH-secreting tumors - the miss study

Maria Berton Alessandro , Prencipe Nunzia , Bertero Luca , Corsico Marina , Cuboni Daniela , Baldi Marco , Bima Chiara , Bianchi Antonio , Mantovani Giovanna , Ferrau Francesco , SARTORATO PAOLA , Gagliardi Irene , Grottoli Silvia

Introduction: First-generation SRL (fg-SRL) represent the treatment of choice in acromegaly patients with post-neurosurgical adenomatous remnant and GH-hypersecretion. Anyway, approximately 60% of patients do not achieve adequate disease control. The main predictors of resistance include male sex, young age, invasiveness of the lesion and its hyperintensity on T2-weighted MRI scans; but also, SSTR2 expression, the cytokeratin pattern, Ki-67 and the presence of AIP gene mutatio...

ea0081p397 | Pituitary and Neuroendocrinology | ECE2022

The cut-off limits of GH response to GHRH + arginine test related to body mass index for the diagnosis of adult GH deficiency: do we need to review our diagnostic criteria?

Cuboni Daniela , Varaldo Emanuele , Bioletto Fabio , Maria Berton Alessandro , Bona Chiara , Prencipe Nunzia , Ghigo Ezio , Maccario Mauro , Grottoli Silvia , Gasco Valentina

Introduction: The diagnosis of GH deficiency (GHD) in adults is based on a reduced GH response to provocative tests. The proportion of patients with low GH response to provocative tests increases with the number of other pituitary hormone deficiencies and several studies involving panhypopituitary patients have shown that under certain circumstances GH stimulation tests may be unnecessary to diagnose GHD.Objective: Aim of this study was to re-evaluate th...

ea0090p709 | Pituitary and Neuroendocrinology | ECE2023

Adrenocortical, somatotropic and antidiuretic response to nasal glucagon in healthy subjects

Varaldo Emanuele , Bioletto Fabio , Cuboni Daniela , Prencipe Nunzia , Bona Chiara , Barale Marco , Ghigo Ezio , Grottoli Silvia , Maria Berton Alessandro , Gasco Valentina

Rationale: In the diagnosis of hypopituitarism, the glucagon stimulation test allows for the simultaneous and safe evaluation of the somatotropic and corticotropic axes; recent data have highlighted a stimulating action also on the neurohypophyseal secretion of arginine-vasopressin. This procedure involves the intramuscular or subcutaneous administration of 1-1.5 mg of glucagon based on the patient’s weight (respectively less or more than 90 kg). Nowadays no data are avai...

ea0063p736 | Pituitary and Neuroendocrinology 2 | ECE2019

Prevalence of silent acromegaly in prolactinomas (PASP): an Italian experience

Bona Chiara , Prencipe Nunzia , Mantonavi Giovanna , Lanzi Roberto , Jaffrain-Rea Marie-Lise , Ambrosio Maria Rosaria , Pasquali Daniela , Vettor Roberto , Cannavo Salvatore , Ghigo Ezio , Grottoli Silvia

Patients with prolactinomas may develop acromegaly during D2-agonists (DA), suggesting the existence of somatomammotroph adenomas with asynchronous secretion of GH and PRL. This may be due to the acquisition of somatotroph characteristics by lactotroph cells or to GH co-secretion by somatommammotroph cells unmasked after PRL inhibition by DA. The prevalence of silent acromegaly in prolactinomas during DA is 4.1%. The purpose of this study was to evaluate the somatotroph axis i...